150479-67-7

Usage

Chemical compound

2-Aminoisophthalamide

Classification

Aminobenzenes

Physical state

Pale yellow solid

Molecular weight

151.16 g/mol

Uses

Building block for pharmaceuticals, dyes, and agrochemicals
Precursor for synthesis of various heterocyclic compounds
Key intermediate in production of organic products

Biological activities

Potential inhibitor of certain enzymes
Utilized in medicinal chemistry research

Upstream product

• 32114-73-1 2-nitrobenzene-1,3-dicarboxamide 
• 81-20-9 2,6-dimethylnitrobenzene 
• 21161-11-5 2-nitroisophthalic acid 

Downstream Products

• 1612242-53-1 C₂₅H₂₇F₃N₆O₃ 
• 1612241-66-3 4-(3-trifluoromethyl-benzylamino)-benzo[d][1,2,3]triazine-8-carboxamide 
• 1612241-86-7 4-((4-(3-(trifluoromethyl)phenyl)piperidin-3-yl)amino)benzo[d][1,2,3]triazine-8-carboxamide 

Relevant academic research and scientific papers

AZAQUINAZOLINE CARBOXAMIDE DERIVATIVES

Novel azaquinazoline carboxamide derivatives of formula (I) wherein W1, W2, W3, W4, R1, R2, R3 and m which are defined above, are p70S6K inhibitor, and can be employed, inter alia, for the treatment of hyperproliferative disorders.

Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives

Derivatives of 2-phenyl quinazolinones are useful for the treatment of patients having precancerous lesions. These compounds are also useful to inhibit growth of neoplastic cells.

QUINAZOLINONE ANTIANGINAL AGENTS

Compounds of formula: and pharmaceutically acceptable salts thereofwhereinR1 is H, Q - Q alkyl, C j -Q alkoxy or CONRsRs;R2 is H or- CJ-C4 alkyl;R3 is C2-C4 alkyl;R4 is H, C2-C4 alkanoyl optionally substituted withNR7R8, (hydroxy)C2-C4 alkyl optionally substitutedwith NR7R8, CH=CHC02R9, CH=CHCONR7R8,CH2CH2C02R9, CH2CH2CONR7R8, S02NR7R8,S02NH(CH2)nNR7R8 or imidazolyl;R5 and Rs are each independently H or C1-C4 alkyl;R7 and R8 are each independently H or C1-C4 alkyl, ortogether with the nitrogen atom to which they areattached form a pyrrolidino, piperidino, morpholino or4-(NR10)-l-piperazinyl group wherein any of saidgroups is optionally substituted with CONR5R6;R9 is H or C1-C4 alkyl;R10 is H, C1-C3 alkyl or (hydroxy)C2-C3 alkyl; andn is 2, 3 or 4;with the proviso that R4 is not H when R1 is H, C1-C4 alkylor C1-C4 alkoxy; are selective cGMP PDE inhibitors usefiilin the treatment of cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.

Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide

A series of new imidazo[5,1-d]-1,2,3,5-tetrazinones with additional hydrogen-bonding or ionic substituents at the 8-carboxamide position of the antitumor drugs temozolomide (1) and mitozolomide (2) has been prepared. None of these compounds were significantly more cytotoxic in vitro against the mouse TLX5 lymphoma than the lead structures. Molecular modeling techniques have been used to design benzo- and pyrazolo[4,3-d]-1,2,3-triazinones bearing carboxamide groups in appropriate positions which are isosteric with temozolomide and mitozolomide but which cannot ring open to alkylating species. As predicted, these compounds have no inhibitory properties against human GM892A or Raji cell lines in vitro. Temozolomide and the spermidine- temozolomide conjugate 28 preferentially methylate guanines within guanine- rich sequences in DNA, but no experimental evidence has been found to support the hypothesis that such regions are involved in catalyzing the ring opening of the imidazotetrazinone prodrugs to their active forms.